TY - JOUR
T1 - Effect of cimetidine and probenecid on pilsicainide renal clearance in humans
AU - Shiga, Tsuyoshi
AU - Hashiguchi, Masayuki
AU - Urae, Akinori
AU - Kasanuki, Hiroshi
AU - Rikihisa, Tadaaki
PY - 2000
Y1 - 2000
N2 - Objective: To investigate the effect of cimetidine and probenecid on the renal clearance of pilsicainide in healthy subjects. Methods: Nine healthy men (age range, 21 to 38 years) were given oral doses of 50 mg pilsicainide hydrochloride alone, with coadministration of 800 mg oral cimetidine, or with coadministration of 1500 mg oral probenecid on three occasions in a Latin- square order. Urine and venous blood samples were collected on a timely basis. The concentration of pilsicainide in plasma and urine were determined by an HPLC method. Results: Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 ± 0.1 to 10.8 ± 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 ± 53.9 to 141.8 ± 25.9 mL/min). The net renal clearance by tubular secretion was significantly reduced by a mean value of 38%, from 151.4 ± 62.9 to 93.0 ± 31.1 mL/min. Coadministration of probenecid did not show any changes in plasma concentrations of pilsicainide, pharmacokinetics, or the net renal clearance by tubular secretion of pilsicainide. Conclusions: Pilsicainide appeared to be secreted by the active transport system for organic bases in the proximal tubule, and the excretion of pilsicainide was inhibited by cimetidine.
AB - Objective: To investigate the effect of cimetidine and probenecid on the renal clearance of pilsicainide in healthy subjects. Methods: Nine healthy men (age range, 21 to 38 years) were given oral doses of 50 mg pilsicainide hydrochloride alone, with coadministration of 800 mg oral cimetidine, or with coadministration of 1500 mg oral probenecid on three occasions in a Latin- square order. Urine and venous blood samples were collected on a timely basis. The concentration of pilsicainide in plasma and urine were determined by an HPLC method. Results: Concomitant administration of cimetidine significantly increased the area under the plasma concentration-time curve of pilsicainide by a mean of 33%, prolonged elimination half-life by a mean of 24% (from 5 to 6.2 hours), reduced apparent oral clearance by a mean of 26% (from 14.7 ± 0.1 to 10.8 ± 0.8 L/h) and reduced renal clearance by a mean of 28% (from 196.8 ± 53.9 to 141.8 ± 25.9 mL/min). The net renal clearance by tubular secretion was significantly reduced by a mean value of 38%, from 151.4 ± 62.9 to 93.0 ± 31.1 mL/min. Coadministration of probenecid did not show any changes in plasma concentrations of pilsicainide, pharmacokinetics, or the net renal clearance by tubular secretion of pilsicainide. Conclusions: Pilsicainide appeared to be secreted by the active transport system for organic bases in the proximal tubule, and the excretion of pilsicainide was inhibited by cimetidine.
UR - http://www.scopus.com/inward/record.url?scp=0034025366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034025366&partnerID=8YFLogxK
U2 - 10.1067/mcp.2000.104018
DO - 10.1067/mcp.2000.104018
M3 - Article
C2 - 10741624
AN - SCOPUS:0034025366
SN - 0009-9236
VL - 67
SP - 222
EP - 228
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 3
ER -